BACKGROUND: The paclitaxel-eluting Taxus-Express stent is superior regarding angiographic and clinical outcome compared with its bare-metal platform for lesions in native coronary arteries. We studied the potential impact of the Taxus-Express stent in comparison with its bare-metal counterpart for treatment of lesions in saphenous vein grafts (SVGs). Furthermore, a meta-analysis was performed regarding use of drug-eluting (DES) vs bare-metal stents (BMS) in SVG lesions. METHODS: We analyzed 13 consecutive patients who underwent percutaneous revascularization in SVG lesions using the slow-release, paclitaxel-eluting Taxus-Express stent. These lesions were balanced with 26 patients with SVG lesions treated with the bare-metal Express stent (BMS) in the preceding period. Angiographic follow-up was performed after 6 months, clinical follow-up after 6 and 12 months. RESULTS: There were no statistically significant differences regarding clinical, procedural and angiographic parameters pre and post intervention. Binary restenoses occurred significantly less in the Taxus group compared with the BMS group (0% vs 34.6%; p=0.016). This translated into a significantly lower occurrence of major adverse cardiac events (death, Q-wave myocardial infarction, repeat target vessel revascularization) in the Taxus group compared with the BMS group at the 6-month (0% vs 26.9%, p=0.039) and 12-month follow-up (7.7% vs 38.5%, p=0.045). Multivariate predictors for freedom of binary restenosis were the reference diameter pre intervention and treatment with Taxus stents. Meta-analysis including 280 DES and 256 BMS patients revealed an odds ratio of 0.34 (95% confidence interval 0.21-0.54) for MACE and 0.26 (95% confidence interval 0.16-0.44) for target vessel revascularizations, both favoring DES. CONCLUSIONS: We conclude that the use of the slow-release Taxus-Express stent has the potential to be superior regarding angiographic and clinical outcome compared with its bare-metal counterpart for treatment of SVG lesions within a 12-month follow-up. A large, randomized trial including a long follow-up period is now required to prove the results of the meta-analysis.
BACKGROUND: The paclitaxel-eluting Taxus-Express stent is superior regarding angiographic and clinical outcome compared with its bare-metal platform for lesions in native coronary arteries. We studied the potential impact of the Taxus-Express stent in comparison with its bare-metal counterpart for treatment of lesions in saphenous vein grafts (SVGs). Furthermore, a meta-analysis was performed regarding use of drug-eluting (DES) vs bare-metal stents (BMS) in SVG lesions. METHODS: We analyzed 13 consecutive patients who underwent percutaneous revascularization in SVG lesions using the slow-release, paclitaxel-eluting Taxus-Express stent. These lesions were balanced with 26 patients with SVG lesions treated with the bare-metal Express stent (BMS) in the preceding period. Angiographic follow-up was performed after 6 months, clinical follow-up after 6 and 12 months. RESULTS: There were no statistically significant differences regarding clinical, procedural and angiographic parameters pre and post intervention. Binary restenoses occurred significantly less in the Taxus group compared with the BMS group (0% vs 34.6%; p=0.016). This translated into a significantly lower occurrence of major adverse cardiac events (death, Q-wave myocardial infarction, repeat target vessel revascularization) in the Taxus group compared with the BMS group at the 6-month (0% vs 26.9%, p=0.039) and 12-month follow-up (7.7% vs 38.5%, p=0.045). Multivariate predictors for freedom of binary restenosis were the reference diameter pre intervention and treatment with Taxus stents. Meta-analysis including 280 DES and 256 BMS patients revealed an odds ratio of 0.34 (95% confidence interval 0.21-0.54) for MACE and 0.26 (95% confidence interval 0.16-0.44) for target vessel revascularizations, both favoring DES. CONCLUSIONS: We conclude that the use of the slow-release Taxus-Express stent has the potential to be superior regarding angiographic and clinical outcome compared with its bare-metal counterpart for treatment of SVG lesions within a 12-month follow-up. A large, randomized trial including a long follow-up period is now required to prove the results of the meta-analysis.
Authors: Clara E E Hanekamp; Jacques J Koolen; Peter Den Heijer; Martin J Schalij; Jan J Piek; Frits W H M Bär; Iwan De Scheerder; Hans J R M Bonnier; Nico H J Pijls Journal: Catheter Cardiovasc Interv Date: 2003-12 Impact factor: 2.692
Authors: William W Chu; Seung-Woon Rha; Pramod K Kuchulakanti; Edouard Cheneau; Rebecca Torguson; Ellen Pinnow; Jana Alexieva-Fournadjiev; Augusto D Pichard; Lowell F Satler; Kenneth M Kent; Joseph Lindsay; Ron Waksman Journal: Am J Cardiol Date: 2005-11-02 Impact factor: 2.778
Authors: Gregg W Stone; Stephen G Ellis; Louis Cannon; J Tift Mann; Joel D Greenberg; Douglas Spriggs; Charles D O'Shaughnessy; Samuel DeMaio; Patrick Hall; Jeffrey J Popma; Joerg Koglin; Mary E Russell Journal: JAMA Date: 2005-09-14 Impact factor: 56.272
Authors: Christian Templin; Arnd Schaefer; Burkhard Stumme; Helmut Drexler; Mario von Depka Journal: Clin Res Cardiol Date: 2006-01-19 Impact factor: 5.460
Authors: M P Savage; J S Douglas; D L Fischman; C J Pepine; S B King; J A Werner; S R Bailey; P A Overlie; S H Fenton; J A Brinker; M B Leon; S Goldberg Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: Gerald S Werner; Andreas Krack; Gero Schwarz; Dirk Prochnau; Stefan Betge; Hans R Figulla Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: Angela Hoye; Pedro A Lemos; Chourmouzios A Arampatzis; Francesco Saia; Kengo Tanabe; Muzaffer Degertekin; Sjoerd Hofma; Eugene McFadden; Georgios Sianos; Pieter C Smits; Willem J van der Giessen; Pim de Feyter; Ron T van Domburg; Patrick W Serruys Journal: J Invasive Cardiol Date: 2004-05 Impact factor: 2.022
Authors: C Herdeg; K Göhring-Frischholz; U Helber; T Geisler; A May; K K Haase; M Gawaz Journal: Clin Res Cardiol Date: 2007-11-22 Impact factor: 5.460
Authors: Martin Unverdorben; Ralf Degenhardt; Marcus Wiemer; Dieter Horstkotte; Henrik Schneider; Christoph Nienaber; Wolfgang Bocksch; Michael Gross; Michael Boxberger; Christian Vallbracht Journal: Clin Res Cardiol Date: 2007-08-23 Impact factor: 5.460
Authors: Pascal Meier; Emmanouil S Brilakis; Roberto Corti; Guido Knapp; Mehdi H Shishehbor; Hitinder S Gurm Journal: PLoS One Date: 2010-06-10 Impact factor: 3.240